The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Mechanisms of Pyrazinamide Action and Resistance
Open accessAbstract
Pyrazinamide (PZA) is a unique antituberculosis (anti-TB) drug that plays a key role in shortening TB therapy. PZA kills nonreplicating persisters that other TB drugs fail to kill, which makes it an essential drug for inclusion in any drug combinations for treating drug-susceptible and drug-resistant TB such as multidrug-resistant TB. PZA acts differently from common antibiotics by inhibiting multiple targets such as energy production, trans-translation, and perhaps pantothenate/coenzyme A required for persister survival. Resistance to PZA is mostly caused by mutations in the pncA gene encoding pyrazinamidase, which is involved in conversion of the prodrug PZA to the active form pyrazinoic acid. Mutations in the drug target ribosomal protein S1 (RpsA) are also found in some PZA-resistant strains. The recent finding that panD mutations are found in some PZA-resistant strains without pncA or rpsA mutations may suggest a third PZA resistance gene and a potential new target of PZA. Current phenotype-based PZA susceptibility testing is not reliable due to false resistance; sequencing of the pncA gene represents a more rapid, cost-effective, and reliable molecular test for PZA susceptibility testing and should be used for guiding improved treatment of multidrug-resistant and extensively multidrug-resistant TB. Finally, the story of PZA has important implications for not only TB therapy but also chemotherapy in general. PZA serves as a model prototype persister drug and hopefully a “tipping point” that inspires new efforts at developing a new type of antibiotic or drug that targets nonreplicating persisters for improved treatment of not only TB but also other persistent bacterial infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 4×
“The subsequent observation in 2005 that bedaquiline (or TMC207, a diarylquinoline), an inhibitor of F1F0 ATP synthase, could synergizewithPZAactivity (37)—afinding just likeDCCD synergy with PZA shown earlier in 2003 (30)—provides further support for the model of PZA.”
BackgroundResultInfluentialBetts, J. C., Lukey, P. T., Robb, L. C., McAdam, R. A., & Duncan, K. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02779.x · Cited by 1,395 · cited 1×
“In addition, it is worth noting that starved M. tuberculosis had increased expression of pncA (36) , which could increase the PncA enzyme levels needed for enhanced conversion of PZA to the active form POA, and may thus contribute to increased killing of tubercle bacilli by PZA under starvation…”
BackgroundWHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Falzon, D., Jaramillo, E., Schünemann, H. J., Arentz, M., Bauer, M., Bayona, J., Blanc, L., Caminero, J. A., Daley, C. L., Duncombe, C., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00073611 · Cited by 1,100
Fox, W., Ellard, G. A., & Mitchison, D. A. (1999) · PubMed · Cited by 797
Self-citationScorpio, A., & Zhang, Y. (1996) · Nature Medicine · doi:10.1038/nm0696-662 · Cited by 726
Self-citationThe curious characteristics of pyrazinamide: a review.
Zhang, Y., & Mitchison, D. A. (2003) · PubMed · Cited by 586
Self-citationThe action of antituberculosis drugs in short-course chemotherapy
Mitchison, D. A. (1985) · Tubercle · doi:10.1016/0041-3879(85)90040-6 · Cited by 518
Self-citationRao, S. P. S., Alonso, S., Rand, L., Dick, T., & Pethe, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711697105 · Cited by 517
Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis
Shi, W., Zhang, X., Jiang, X., Yuan, H., Lee, J. S., Barry, C. E., Wang, H., Zhang, W., & Zhang, Y. (2011) · Science · doi:10.1126/science.1208813 · Cited by 514
Self-citationZhang, Y. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg446 · Cited by 477
Self-citationTHE MAGIC BULLETS AND TUBERCULOSIS DRUG TARGETS
Zhang, Y. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100120 · Cited by 432
Self-citationFalzon, D., Jaramillo, E., & Schünemann, H. J. (2011) · European Respiratory Journal · doi:10.1183/13993003/erj.38.suppl_55.393 · Cited by 393
Sambandamurthy, V. K., Wang, X., Chen, B., Russell, R. G., Derrick, S., Collins, F. M., Morris, S. L., & Jacobs, W. R. (2002) · Nature Medicine · doi:10.1038/nm765 · Cited by 336
Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis
Scorpio, A., Lindholm-Levy, P., Heifets, L., Gilman, R., Siddiqi, S., Cynamon, M., & Zhang, Y. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.540 · Cited by 333
Self-citationMcCune, R. M., Feldmann, F. M., Lambert, H. P., & McDermott, W. (1966) · The Journal of Experimental Medicine · doi:10.1084/jem.123.3.445 · Cited by 310
McCune, R. M., Tompsett, R., & McDermott, W. (1956) · The Journal of Experimental Medicine · doi:10.1084/jem.104.5.763 · Cited by 307
Zhang, Y., Scorpio, A., Nikaido, H., & Sun, Z. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.7.2044-2049.1999 · Cited by 285
Self-citationZimhony, O., Cox, J. S., Welch, J. T., Vilchèze, C., & Jacobs, W. R. (2000) · Nature Medicine · doi:10.1038/79558 · Cited by 270
McCune, R. M., & Tompsett, R. (1956) · The Journal of Experimental Medicine · doi:10.1084/jem.104.5.737 · Cited by 260
Kim, J.-J., Lee, H.-M., Shin, D.-M., Kim, W., Yuk, J.-M., Jin, H. S., Lee, S.-H., Cha, G.-H., Kim, J.-M., Lee, Z.-W., et al. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.03.008 · Cited by 244
Keiler, K. C. (2008) · Annual Review of Microbiology · doi:10.1146/annurev.micro.62.081307.162948 · Cited by 235
Persisters, persistent infections and the Yin–Yang model
Zhang, Y. (2014) · Emerging Microbes & Infections · doi:10.1038/emi.2014.3 · Cited by 233
Self-citationDaily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model
Rosenthal, I. M., Zhang, M., Williams, K. N., Peloquin, C. A., Tyagi, S., Vernon, A. A., Bishai, W. R., Chaisson, R. E., Grosset, J. H., & Nuermberger, E. L. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040344 · Cited by 205
Tasneen, R., Li, S.-Y., Peloquin, C. A., Taylor, D., Williams, K. N., Andries, K., Mdluli, K. E., & Nuermberger, E. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05293-11 · Cited by 194
Synergistic Activity of R207910 Combined with Pyrazinamide against Murine Tuberculosis
Ibrahim, M., Andries, K., Lounis, N., Chauffour, A., Truffot-Pernot, C., Jarlier, V., & Veziris, N. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00898-06 · Cited by 175
Cheng, S.-J., Thibert, L., Sanchez, T., Heifets, L., & Zhang, Y. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.528-532.2000 · Cited by 175
Self-citationZhang, S., Chen, J., Shi, W., Liu, W., Zhang, W., & Zhang, Y. (2013) · Emerging Microbes & Infections · doi:10.1038/emi.2013.38 · Cited by 160
Self-citationMcCune, R. M., Feldmann, F. M., & McDermott, W. (1966) · The Journal of Experimental Medicine · doi:10.1084/jem.123.3.469 · Cited by 157
Boshoff, H. I., Mizrahi, V., & Barry, C. E. (2002) · Journal of Bacteriology · doi:10.1128/jb.184.8.2167-2172.2002 · Cited by 152
Requirement of transfer‐messenger RNA for the growth of Bacillus subtilis under stresses
Muto, A., Fujihara, A., Ito, K., Matsuno, J., Ushida, C., & Himeno, H. (2000) · Genes to Cells · doi:10.1046/j.1365-2443.2000.00356.x · Cited by 131
Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis
Byrne, S. T., Denkin, S. M., & Zhang, Y. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl486 · Cited by 131
Self-citationStoffels, K., Mathys, V., Fauville‐Dufaux, M., Wintjens, R. T., & Bifani, P. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05385-11 · Cited by 110
Crystal Structure and Mechanism of Catalysis of a Pyrazinamidase from Pyrococcus horikoshii
Du, X., Wang, W., Kim, R., Yakota, H., Nguyen, H., & Kim, S. (2001) · Biochemistry · doi:10.1021/bi0115479 · Cited by 105
Tasneen, R., Tyagi, S. K., Williams, K. N., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00686-08 · Cited by 101
Characterization of Mycobacterium tuberculosis nicotinamidase/pyrazinamidase
Zhang, H., Deng, J., Bi, L., Zhou, Y., Zhang, Z., Zhang, C., Zhang, Y., & Zhang, X. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2007.06241.x · Cited by 98
Self-citationThe search for new sterilizing anti-tuberculosis drugs
Denis, A. M. (2004) · Frontiers in bioscience · doi:10.2741/1293 · Cited by 89
Thibonnier, M., Thiberge, J.-M., & Reuse, H. D. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003810 · Cited by 88
Mestdagh, M., Fonteyne, P.-A., Realini, L., Rossau, R., Jannes, G., Mijs, W., Smet, K. A. L. D., Portaels, F., & den Eeckhout, E. V. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.9.2317 · Cited by 86
Current development and future prospects in chemotherapy of tuberculosis
Nuermberger, E. L., Spigelman, M., & Yew, W. W. (2010) · Respirology · doi:10.1111/j.1440-1843.2010.01775.x · Cited by 80
Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis
Wade, M. M., & Zhang, Y. (2004) · Journal of Medical Microbiology · doi:10.1099/jmm.0.45639-0 · Cited by 80
Self-citationInhibition of Isolated Mycobacterium tuberculosis Fatty Acid Synthase I by Pyrazinamide Analogs
Ngo, S. C., Zimhony, O., Chung, W. J., Sayahi, H., Jacobs, W. R., & Welch, J. T. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01458-06 · Cited by 79
Tarshis, M. S., & WEED, W. A. (1953) · PubMed · doi:10.1164/art.1953.67.3.391 · Cited by 74
Véziris, N., Ibrahim, M., Lounis, N., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1736oc · Cited by 70
Somoskövi, Á., Dormandy, J., Parsons, L. M., Kaswa, M. K., Goh, K. S., Rastogi, N., & Salfinger, M. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.01454-06 · Cited by 65
Foreword from the Co-Editor-in-Chief
Brennan, P. J. (2001) · Tuberculosis · doi:10.1054/tube.2001.0288 · Cited by 64
Wade, M. M., & Zhang, Y. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl358 · Cited by 61
Self-citationIron enhances the antituberculous activity of pyrazinamide
Somoskövi, Á. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh042 · Cited by 58
Andries, K., Gevers, T., & Lounis, N. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00934-10 · Cited by 54
Mycobacterium canettii is intrinsically resistant to both pyrazinamide and pyrazinoic acid
Feuerriegel, S., Köser, C. U., Richter, E., & Niemann, S. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt042 · Cited by 52
Zhang, Y., Chang, K. C., Leung, C.-C., et al. (2012) · Emerging Microbes & Infections · doi:10.1038/emi.2012.18 · Cited by 47
Self-citationKinetics and Inhibition of Nicotinamidase from Mycobacterium tuberculosis
Seiner, D. R., Hegde, S. S., & Blanchard, J. S. (2010) · Biochemistry · doi:10.1021/bi1011157 · Cited by 36
Huang, Q., Chen, Z.-F., Li, Y.-Y., Zhang, Y., Ren, Y., Fu, Z., & Xu, S. (2007) · Chemotherapy · doi:10.1159/000107723 · Cited by 28
Self-citationEmerging drugs for the treatment of tuberculosis
Yew, W. W., Cynamon, M. H., & Zhang, Y. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.521497 · Cited by 25
Self-citationEffects of low incubation temperatures on the bactericidal activity of anti-tuberculosis drugs
Coleman, D., Waddell, S. J., & Mitchison, D. A. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq414 · Cited by 12
Self-citation
Cited by
Lysogeny in nature: mechanisms, impact and ecology of temperate phages
Howard-Varona, C., Hargreaves, K. R., Abedon, S. T., & Sullivan, M. B. (2017) · The ISME Journal · doi:10.1038/ismej.2017.16 · Cited by 894
Bacterial persisters: molecular mechanisms and therapeutic development
Niu, H., Gu, J., & Zhang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01866-5 · Cited by 310
Self-citationThe Concept of an Ideal Antibiotic: Implications for Drug Design
Gajdács, M. (2019) · Molecules · doi:10.3390/molecules24050892 · Cited by 271
Are all antibiotic persisters created equal?
Shultis, M. W., Mulholland, C. V., & Berney, M. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.933458 · Cited by 19
Metadata
- Authors
- Zhang, Y., Shi, W., Zhang, W., & Mitchison, D.
- Venue
- Microbiology Spectrum
- Publisher
- American Society for Microbiology
- Published
- 2014-08-15
- Volume
- 2
- Issue
- 4
- Pages
- 1-0023
- ISSN
- 2165-0497 (ISSN-L)
- OpenAlex
- W2046352089
- Cited by
- 332
- References
- 54
- FWCI
- 14.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.